These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Expressions and their clinical significance of bcl-2 and nm23 in epithelial ovarian carcinoma].
    Author: Cao LQ, Chen XM, Li X.
    Journal: Hunan Yi Ke Da Xue Xue Bao; 2000 Apr 28; 25(2):188-90. PubMed ID: 12212220.
    Abstract:
    The expressions of bcl-2 and nm23 protein in epithelial ovarian carcinoma were analyzed by immunohistochemical method. The results were that 1. the positive expression of bcl-2 protein was 60% (27/45) in epithelial carcinoma; the positive expression of bcl-2 protein in Grade I was 31.25% (5/16), in Grade II 57.14% (8/14), in Grade III 93.33% (14/15) and there were significant differences among them (P < 0.05); 2. the positive expression of nm23 protein was 40% (18/45) in epithelial carcinoma; the positive expression of bcl-2 protein in Stage I/II was 57.1% (12/21), in Stage III/IV 25% (6/24), and there was significant difference between them (P < 0.05). We conclude that the expressions of bcl-2 and nm23 protein are associated with tumor differentiation and clinical stage respectively. Analyzing the expressions of bcl-2 and nm23 are beneficial to the prognosis of the ovarian tumor patients.
    [Abstract] [Full Text] [Related] [New Search]